ClinicalTrials.gg
CompletedNCT03004742Updated Feb 2, 2017

Flavonoid-rich Supplement Influence on the Human Metabolome

An interventional study of Flavonoid and Placebo in Inflammation, sponsored by Appalachian State University. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-02.

Sponsored by Appalachian State University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Aug 2015, registered Dec 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Inflammation by Appalachian State University — none open to participants now, none under way, none of them phase 3. Inflammation · Appalachian State University.

Enrollment
Largest of 19
110 · median 40
Started
2015
with 1 other
No phase
19 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies in Inflammation by Appalachian State University, this one has the largest enrollment, is one of 2 that started in 2015, is one of 19 with no phase, and was the 9th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

None of the 19 studies in Inflammation by Appalachian State University is open now. The open studies under Inflammation, anywhere →

Where they have run

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 18 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Inflammation by Appalachian State University as a file.
02

Study summary

This study will measure the effect of ingesting a flavonoid-rich supplement on various biomarkers in overweight/obese women during a 12-week period. The flavonoid-rich supplement contains a mixture of flavonoids including quercetin, catechins from green tea extract, and anthocyanins from bilberry extract, and other food components that facilitate flavonoid bioactivity including fish oil, caffeine, and vitamin C.

Read the detailed description
  1. The primary objective of this study is to evaluate the effect of ingesting a flavonoid-rich supplement on total urine polyphenol concentration and shifts in blood metabolites related to flavonoid intake in healthy but overweight/obese community-dwelling adults.
  2. Secondary objectives are to determine related effects on measures of inflammation and oxidative stress. Studies are mixed regarding the influence of flavonoid supplements on traditional biomarkers for inflammation and oxidative stress, and metabolite shifts from the metabolomics measurements may provide better insights. Chemistry profiles and symptom logs will be compared pre- and post-study between groups to confirm prior safety data collected on human participants.

Hypothesis: Subjects randomized to ingestion of the flavonoid-rich supplement compared to placebo will experience an increase in total urine polyphenols concentrations and shifts in blood metabolites related to increased flavonoid metabolism. Secondarily, subjects ingesting the flavonoid-rich supplement will experience a decrease in systemic inflammation and oxidative stress.

BASELINE TESTING (ASU-NCRC HUMAN PERFORMANCE LAB):

A. One week before the start of the study, subjects will report to the ASU-NCRC Human Performance Lab, be oriented to the study, and provide voluntary consent. Subjects will fill in a medical health questionnaire to verify medical history and lifestyle habits. Subjects must agree to maintain normal dietary and physical activity patterns during the 12-week intervention, and not make formal attempts to lose body weight. All other subject inclusion and exclusion criteria must be maintained during the study. Subjects will be instructed on how to record all food intake during a 3-day period prior to the start of the study (Thursday, Friday, and Sunday).

Subjects will be instructed on how to collect urine for 24-hours during the day just before the study starts. Urine collection guidelines:

  • You should collect every drop of urine during each 24-hour period. It does not matter how much or little urine is passed each time, as long as every drop is collected.
  • Begin the urine collection in the morning after you wake up, after you have emptied your bladder for the first time.
  • Urinate (empty the bladder) for the first time and flush it down the toilet. Note the exact time (eg, 6:15 AM). You will begin the urine collection at this time.
  • Collect every drop of urine during the day and night in an empty collection bottle. Store the bottle in the refrigerator. Be sure to collect any urine passed during bowel movements.
  • Finish by collecting the first urine passed the next morning, adding it to the collection bottle. This should be within ten minutes before or after the time of the first morning void on the first day (which was flushed). In this example, you would try to void between 6:05 and 6:25 on the second day. If you need to urinate one hour before the final collection time, drink a full glass of water so that you can void again at the appropriate time. If you have to urinate 20 minutes before, try to hold the urine until the proper time.
  • Please note the exact time of the final collection.

B. On the first day of the study, subjects will return to the lab in a fasted state (9 or more hours with no food or beverage other than water) and turn in the 3-day food record and the 24-h urine collection sample. Height, body weight, and percent body fat (seca BIA scale) will be measured. Blood samples will be collected from an antecubital vein with subjects in the seated position by trained phlebotomists. Each blood sample will not exceed 40 ml (2.7 tablespoons). Subjects will also record responses to a 4-week retrospective symptom log. Subjects will be given flavonoid or placebo supplements for the first 4-week period, and ingest the first two supplements in the lab under supervision.

12-WEEK INTERVENTION: Subjects (N=110) will be randomized to the flavonoid supplement or placebo supplement groups for 12 weeks (thus two independent groups run in parallel with 55 subjects). Supplements will be administered in a double-blinded manner, with the code held by Reoxcyn Discoveries Group until the end of the study. The goal is for N=100 subjects to complete all phases of the study. Subjects will ingest two supplement supplements each day of the study, one before breakfast, and the second one before lunch.

Subjects will report to the Human Performance Lab at the 4- and 12-week time points in an overnight-fasted state and repeat all baseline measurements (including the 3-day food record and 24-h urine collection). The 4-week retrospective symptom logs will be filled in at pre-study, 4, 8, and 12 weeks (with the 8-week log administered via email). Subjects will be given an 8-weeks supply of the supplement after completing the 4-week lab session.

SUPPLEMENT INFORMATION:

The flavonoid-rich supplement contains a mixture of flavonoids from green tea and bilberry extracts, and quercetin. The supplement also contains food components that boost flavonoid benefits in the body including fish oil, caffeine, and vitamin C.

The daily dose will be 4 flavonoid tablets (two before breakfast, two before lunch).

Here is a detailed summary of the ingredients of the flavonoid-rich supplement (4 tablets per day):

Supplement Facts Serving size: 4 Tablets Servings per container: 30 Amount per Serving % Daily Value Calories 50 Total Carbohydrate 12 g 4% Sugars 10 g Vitamin C (as Ascorbyl Palmitate) 100 mg 167% Wild Bilberry Fruit Extract (std. min. 25% Total Anthocyanins) 156 mg ** Green Tea Leaf Extract 180 mg ** Quercetin 100 mg ** Natural Caffeine (from Coffea arabica Bean) 100 mg ** NovoOmega® Omega-3 F30 Powder (Std. 30% Omega-3 Fatty Acids (Eicosapentaenoic Acid and Docosahexaenoic Acid)) 200 mg ** * Percent Daily Values are based on a 2,000 calorie diet

** Daily Value not Established Other Ingredients: Sugar, Natural \& Artificial Flavor, Dextrose, Cellulose Gum, Sucralose, Bamboo Whole Plant Extract, Guar Gum, Xanthan Gum, Citric Acid, Malic Acid, L-Tartaric Acid Contains Fish.

In general, the flavonoid-rich chewable tablets (4 per day) will provide the equivalent quantity of flavonoids as found in 10 apples, one cup of green tea, and one-fourth cup of bilberries. Consuming 4 tablets per day will add approximately 50% more of the beneficial polyphenols typically consumed by adults.

03

Conditions studied

  • Inflammation

Browse trials for

Keywords

  • polyphenols
  • metabolomics
  • oxidative stress
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 25 kg/m2 and higher (about 25 pounds or more overweight from recommended levels)
  • Generally healthy and without chronic disease including cardiovascular disease (e.g., heart disease, stroke), cancer, type 1 diabetes, rheumatoid arthritis
  • Willingness to maintain normal physical activity and diet habits, and make no formal attempts to lose weight during the 12-week study.

Exclusion criteria

Exclusion Criteria:

  • Use of Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) within the past one to two weeks, and plans to use NSAIDs during the 12-week period of the study. Examples include ibuprofen (Advil, Motrin, Nuprin), naproxen (Aleve, Naprosyn), and COX-2 inhibitors (Celebrex).
  • Regular use of fish oil supplements, omega 3 supplements, or omega 3-based drugs (Lovaza, etc.) during the past one to two weeks and plans to use these supplements during the study.
  • History of allergy or intolerance to green tea, blueberries, fish oil, caffeine, or the flavonoid quercetin.
  • Pregnant or breastfeeding
  • Currently on a weight reducing plan or using weight-loss medications (e.g., selective serotonin reuptake inhibitors, , Ritalin, appetite suppressors, Xenical, Diethylpropion), and plans to continue during the 12-week period of the study.
  • Regular use of large dose nutrient, herbal, and dietary supplements during the past one to two weeks, and plans to use these during the 12-week period of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Flavonoid

    Flavonoid supplement

    Dietary Supplement: Flavonoid

  • Placebo comparator
    Placebo

    Placebo

    Dietary Supplement: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Urine phenolics

    24-h urine samples collected pre-study and after 12-weeks intervention

    Time frame: Change from baseline urine phenolics at 12 weeks

Secondary outcomes

  1. Change in global metabolomics

    Blood sample analysis for shifts in metabolites pre-study and after 12-weeks intervention

    Time frame: Change from baseline global metabolomics at 12 weeks

  2. Change in symptoms

    A 4-week retrospective symptom log will be administered pre-study, 4-weeks, 8-weeks, and 12-weeks to document potential adverse gastrointestinal and mental effects.

    Time frame: Change from baseline symptoms at 4-weeks, 8-weeks, 12-weeks.

  3. Change in oxidized LDL

    plasma oxidized LDL

    Time frame: Change from baseline oxidized LDL at 12 weeks

  4. Change in blood diagnostic chemistries

    Comprehensive blood diagnostic chemistry panels

    Time frame: Change from baseline diagnostic chemistries at 12 weeks

  5. Change in CRP

    C-reactive protein

    Time frame: Change from baseline CRP at 12 weeks

  6. Change in IL-6

    Plasma IL-6

    Time frame: Change from baseline IL-6 at 12 weeks

  7. Change in MCP-1

    Plasma MCP-1

    Time frame: Change from baseline MCP-1 at 12 weeks

  8. Change in FRAP

    Plasma FRAP

    Time frame: Change from baseline FRAP at 12 weeks

07

Study locations

1 site
  • Appalachian State University Human Performance Lab, North Carolina Research Campus
    Kannapolis, North Carolina 28081, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared through the Human Metabolome Database (HMDB), other public web sites, and publication in the scientific literature.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jun 2016, 10 months.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 10 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 29, 2016
StartActual
Aug 2015
Primary completionActual
Jun 2016
CompletionActual
Dec 2016
Last update
Feb 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03004742
Lead sponsor
Appalachian State University
Collaborators
Reoxcyn Discoveries Group
Responsible party
Sponsor
First posted
Dec 29, 2016
Start date
Aug 2015
Primary completion
Jun 2016
Completion
Dec 2016
Last update
Feb 2, 2017

Study contacts

David C Nieman, DrPH
principal investigator · Appalachian State Univ

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Flavonoids · Flavonols · Dietary Flavonoid

Start the discussion